Siemens and Nanjing Sandiji Medical Technology Co., LTD. (Sandiji) today signed a strategic cooperation agreement, based on Siemens' leading products and digital solutions, the two parties will cooperate in the field of tablet additive manufacturing digital laboratory, preventive maintenance, pharmaceutical continuous production and other areas, to establish a long-term strategic partnership. And will jointly promote the continuous, digital and intelligent development of China's pharmaceutical t
Siemens and Nanjing Sandiji Medical Technology Co., LTD. (Sandiji) today signed a strategic cooperation agreement, based on Siemens' leading products and digital solutions, the two parties will cooperate in the field of tablet additive manufacturing digital laboratory, preventive maintenance, pharmaceutical continuous production and other areas, to establish a long-term strategic partnership. And will jointly promote the continuous, digital and intelligent development of China's pharmaceutical technology.
Zhang Jinsong, senior vice President of Siemens Digital Industry Group and General Manager of East China Region, Siemens (China) Co., LTD., said: "The strategic cooperation between Siemens and Sandiji is a strong alliance between a digital leader and a 3D printing pharmaceutical leader. Siemens has a complete solution and rich experience in the field of 3D printing and pharmaceutical digitalization. This innovative way of combining 3D printing technology and pharmaceutical digitalization can connect R&D and production to achieve end-to-end transformation from demand to delivery. We look forward to exploring the digital future of the pharmaceutical industry with the Sandiji through this cooperation. "
Dr. Hei Narimori, Founder and CEO of Sandiji, said: "The strategic cooperation between Sandiji and Siemens has broadened the industry's imagination of pharmaceutical digitalization. The MED 3D printing technology of the Triassic is a digital pharmaceutical underlying process, laying the cornerstone of digital pharmaceuticals. It makes the drug from development to market has a new research and development paradigm, from production to supply has a new production and management model. Sandiji's digital pharmaceutical technology platform will be open to more major digital technology providers to jointly promote the process of pharmaceutical 4.0."
Under the agreement, Siemens will provide Sandiji with the world's most advanced technology solutions and products in the field of automation and digitalization, and support the development of drug research and development and production equipment for its global innovative MED 3D printing process. With the goal of "digitalization of the pharmaceutical industry", the two sides will cooperate in the fields of drug research and development and production digitalization, pharmaceutical continuous and paperless production, real-time testing and release of drugs, construction and operation and maintenance of new integrated pharmaceutical factories, and comprehensively expand the application of digital technology in the pharmaceutical industry. At the same time, with years of exploration and experience accumulation in the field of 3D printing and pharmaceutical, the two teams continue to improve the production capacity of MED 3D printing pharmaceutical technology.
In the future, the two parties will also carry out technical discussions and in-depth cooperation in digital construction such as digital virtual laboratories, digital virtual factories, and Internet of Things systems to help build a world-leading smart pharmaceutical center in Sandiji.
Founded in July 2015, Sandiji is committed to building a new 3D printing drug technology platform, covering the full chain of drug dosage form design, digital development and intelligent production.
